Busulfanum

Marginal Zone Lymphoma

Masonic Cancer Center, University of MinnesotaSmall moleculePhase 2Active

BB

69/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 57/ 100
Competitive Position: 89/ 100

Competitive context

99 Active assets in the Marginal Zone Lymphoma cohort.

Asset / Sponsor	Phase	Rating
Etoposide University of Miami	Phase 2	BBB
Orelabrutinib Henan Cancer Hospital	Phase 4	BBB
Vincristine Sulfate Mayo Clinic	Phase 2	BBB
Nivestim Fred Hutchinson Cancer Center	Phase 2	BBB
Cyclosporin A Fred Hutchinson Cancer Center	Phase 2	BBB

View all 50 →

Same molecule, other indications

Busulfanum is also rated in:

myelodysplastic/myeloproliferative neoplasmActive

BBB

Indicative · Phase 2/3

76 / 100

graft versus host diseaseActive

BBB

Indicative · Phase 4

74 / 100

disease related to hematopoietic stem cell transplantActive

BBB

Indicative · Phase 3

74 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.